Patents by Inventor Yangmi LIM

Yangmi LIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEIN COMPRISING ANTI-MESOTHELIN ANTIBODY, ANTI-CD3 ANTIBODY OR ANTI-EGFR ANTIBODY, BISPECIFIC OR TRISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
    Publication number: 20220251176
    Abstract: A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
    Type: Application
    Filed: December 16, 2019
    Publication date: August 11, 2022
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Yangmi LIM, Shinai LEE, Jonghwa WON, Yong-Yea PARK, Aerin YOON, Sua LEE, Okjae LIM, Sojung LIM, Munkyung KIM
  • Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor
    Patent number: 11198733
    Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: December 14, 2021
    Assignees: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Jong-hwa Won, Yangmi Lim, Min-Kyu Hur
  • PHARMACEUTICAL COMPOSITION FOR INHIBITING METASTASIS OF CANCER, COMPRISING, AS ACTIVE INGREDIENT, ANTIBODY THAT SPECIFICALLY BINDS TO EPIDERMAL GROWTH FACTOR RECEPTOR
    Publication number: 20190119388
    Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
    Type: Application
    Filed: April 27, 2016
    Publication date: April 25, 2019
    Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Jong-hwa WON, Yangmi LIM, Min-Kyu HUR